{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:37:15Z","timestamp":1794580635502,"version":"4.9.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"SynAD postdoctoral fellowships"},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP-84480"],"award-info":[{"award-number":["MOP-84480"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Evidence suggests that increased level\/aggregation of \u03b2-amyloid (A\u03b2) peptide, together with enhanced phosphorylation\/aggregation of tau protein, play a critical role in the development of Alzheimer\u2019s disease (AD), the leading cause of dementia in the elderly. At present, AD diagnosis is based primarily on cognitive assessment, neuroimaging, and immunological assays to detect altered levels\/deposition of A\u03b2 peptides and tau protein. While measurement of A\u03b2 and tau in the cerebrospinal fluid\/blood can indicate disease status, neuroimaging of aggregated A\u03b2 and tau protein in the brain using positron emission tomography (PET) enable to monitor the pathological changes in AD patients. With advancements in nanomedicine, several nanoparticles, apart from drug-delivery, have been used as a diagnostic agent to identify more accurately changes in AD patients. Recently, we reported that FDA approved native PLGA nanoparticles can interact with A\u03b2 to inhibit its aggregation\/toxicity in cellular and animal models of AD. Here, we reveal that fluorescence labelled native PLGA following acute intracerebellar injection can identify majority of the immunostained A\u03b2 as well as Congo red labelled neuritic plaques in the cortex of 5xFAD mice. Labelling of plaques by PLGA is apparent at 1\u00a0h, peak around 3\u00a0h and then start declining by 24 h after injection. No fluorescent PLGA was detected in the cerebellum of 5xFAD mice or in any brain regions of wild-type control mice following injection. These results provide the very first evidence that native PLGA nanoparticles can be used as a novel nano-theragnostic agent in the treatment as well as diagnosis of AD pathology.<\/jats:p>","DOI":"10.1186\/s12951-023-01957-5","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T03:09:03Z","timestamp":1688958543000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Detection of \u03b2-amyloid aggregates\/plaques in 5xFAD mice by labelled native PLGA nanoparticles: implication in the diagnosis of Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"21","author":[{"given":"Karthivashan","family":"Govindarajan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyabrata","family":"Kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,10]]},"reference":[{"key":"1957_CR1","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med. 2016;8:595\u2013608.","journal-title":"EMBO Mol Med"},{"key":"1957_CR2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/msj.20157","volume":"77","author":"DP Perl","year":"2010","unstructured":"Perl DP. Neuropathology of Alzheimer\u2019s disease. Mt Sinai J Med. 2010;77:32\u201342.","journal-title":"Mt Sinai J Med"},{"key":"1957_CR3","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","volume":"20","author":"B Dubois","year":"2021","unstructured":"Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, Cappa S, Bejanin A, Bombois S, Epelbaum S, Teichmann M. Clinical diagnosis of Alzheimer\u2019s disease: recommendations of the International Working Group. Lancet Neurol. 2021;20:484\u201396.","journal-title":"Lancet Neurol"},{"key":"1957_CR4","doi-asserted-by":"crossref","unstructured":"Pemberton HG, Collij LE, Heeman F, Bollack A, Shekari M, Salvad\u00f3 G, Alves IL, Garcia DV, Battle M, Buckley C. Quantification of amyloid PET for future clinical use: a state-of-the-art review. Eur J Nucl Med Mol Imag 2022:1\u201321.","DOI":"10.1007\/s00259-022-05784-y"},{"key":"1957_CR5","first-page":"412","volume":"1","author":"N Mattsson","year":"2015","unstructured":"Mattsson N, Carrillo MC, Dean RA, Devous Sr MD, Nikolcheva T, Pesini P, Salter H, Potter WZ, Sperling RS, Bateman RJ. Revolutionizing Alzheimer\u2019s disease and clinical trials through biomarkers. Alzheimer\u2019s & Dementia: Diagnosis Assessment & Disease Monitoring. 2015;1:412\u20139.","journal-title":"Alzheimer\u2019s & Dementia: Diagnosis Assessment & Disease Monitoring"},{"key":"1957_CR6","doi-asserted-by":"crossref","unstructured":"Maschio C, Ni R. Amyloid and tau Positron Emission Tomography Imaging in Alzheimer\u2019s Disease and other tauopathies. Front Aging Neurosci 2022, 14.","DOI":"10.3389\/fnagi.2022.838034"},{"key":"1957_CR7","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S1474-4422(20)30314-8","volume":"19","author":"G Ch\u00e9telat","year":"2020","unstructured":"Ch\u00e9telat G, Arbizu J, Barthel H, Garibotto V, Law I, Morbelli S, van de Giessen E, Agosta F, Barkhof F, Brooks DJ. Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer\u2019s disease and other dementias. Lancet Neurol. 2020;19:951\u201362.","journal-title":"Lancet Neurol"},{"key":"1957_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/B978-0-12-394816-8.00002-7","volume":"64","author":"AD Cohen","year":"2012","unstructured":"Cohen AD, Rabinovici GD, Mathis CA, Jagust WJ, Klunk WE, Ikonomovic MD. Using Pittsburgh compound B for in vivo PET imaging of fibrillar amyloid-beta. Adv Pharmacol. 2012;64:27\u201381.","journal-title":"Adv Pharmacol"},{"key":"1957_CR9","doi-asserted-by":"publisher","first-page":"198","DOI":"10.2967\/jnumed.108.057984","volume":"50","author":"MT Fodero-Tavoletti","year":"2009","unstructured":"Fodero-Tavoletti MT, Rowe CC, McLean CA, Leone L, Li Q-X, Masters CL, Cappai R, Villemagne VL. Characterization of PiB binding to white matter in Alzheimer disease and other dementias. J Nucl Med. 2009;50:198\u2013204.","journal-title":"J Nucl Med"},{"key":"1957_CR10","doi-asserted-by":"crossref","unstructured":"Krishnadas N, Villemagne VL, Dor\u00e9 V, Rowe CC. Advances in brain amyloid imaging. Semin Nucl Med. Elsevier; 2021: 241\u201352.","DOI":"10.1053\/j.semnuclmed.2020.12.005"},{"key":"1957_CR11","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s13311-021-01026-5","volume":"18","author":"RF Buckley","year":"2021","unstructured":"Buckley RF. Recent advances in imaging of preclinical, sporadic, and autosomal Dominant Alzheimer\u2019s Disease. Neurotherapeutics. 2021;18:709\u201327.","journal-title":"Neurotherapeutics"},{"key":"1957_CR12","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.3390\/pharmaceutics14061117","volume":"14","author":"T Pardo-Moreno","year":"2022","unstructured":"Pardo-Moreno T, Gonz\u00e1lez-Acedo A, Rivas-Dom\u00ednguez A, Garc\u00eda-Morales V, Garc\u00eda-Cozar FJ. Ramos-Rodr\u00edguez JJ, Melguizo-Rodr\u00edguez L: Therapeutic Approach to Alzheimer\u2019s Disease: current treatments and new perspectives. Pharmaceutics. 2022;14:1117.","journal-title":"Pharmaceutics"},{"key":"1957_CR13","doi-asserted-by":"crossref","unstructured":"Gabathuler R. Blood-brain barrier transport of drugs for the treatment of brain diseases. CNS & neurological Disorders-Drug targets (formerly current drug Targets-CNS & neurological Disorders) 2009, 8:195\u2013204.","DOI":"10.2174\/187152709788680652"},{"key":"1957_CR14","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s11481-016-9698-1","volume":"12","author":"J Meng","year":"2017","unstructured":"Meng J, Agrahari V, Youm I. Advances in targeted drug delivery approaches for the central nervous system tumors: the inspiration of nanobiotechnology. J Neuroimmune Pharmacol. 2017;12:84\u201398.","journal-title":"J Neuroimmune Pharmacol"},{"key":"1957_CR15","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.apsb.2016.05.013","volume":"6","author":"H Gao","year":"2016","unstructured":"Gao H. Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharm Sinica B. 2016;6:268\u201386.","journal-title":"Acta Pharm Sinica B"},{"key":"1957_CR16","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.2174\/1389450122999210104205018","volume":"22","author":"I Kaur","year":"2021","unstructured":"Kaur I, Kumar A, Behl T, Setia D. Recent advances in nanotechnology-based drug delivery approaches for Alzheimer disease. Curr Drug Targets. 2021;22:1404\u201323.","journal-title":"Curr Drug Targets"},{"key":"1957_CR17","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.2174\/1389557518666171215150024","volume":"18","author":"T-J Ma","year":"2018","unstructured":"Ma T-J, Gao J, Liu Y, Zhuang J-H, Yin C, Li P, Mao L, Xu J, Xu Y-X, Li Y-P. Nanomedicine strategies for sustained, controlled and targeted treatment of Alzheimer\u2019s disease. Mini Rev Med Chem. 2018;18:1035\u201346.","journal-title":"Mini Rev Med Chem"},{"key":"1957_CR18","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40199-018-0221-5","volume":"26","author":"MA Vakilinezhad","year":"2018","unstructured":"Vakilinezhad MA, Amini A, Akbari Javar H, Baha\u2019addini Beigi Zarandi BF, Montaseri H, Dinarvand R. Nicotinamide loaded functionalized solid lipid nanoparticles improves cognition in Alzheimer\u2019s disease animal model by reducing tau hyperphosphorylation. DARU J Pharm Sci. 2018;26:165\u201377.","journal-title":"DARU J Pharm Sci"},{"key":"1957_CR19","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1163\/156856206775997322","volume":"17","author":"CE Astete","year":"2006","unstructured":"Astete CE, Sabliov CM. Synthesis and characterization of PLGA nanoparticles. J Biomater Sci Polym Ed. 2006;17:247\u201389.","journal-title":"J Biomater Sci Polym Ed"},{"key":"1957_CR20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s40005-019-00439-x","volume":"49","author":"EM Elmowafy","year":"2019","unstructured":"Elmowafy EM, Tiboni M, Soliman ME. Biocompatibility, biodegradation and biomedical applications of poly (lactic acid)\/poly (lactic-co-glycolic acid) micro and nanoparticles. J Pharm Invest. 2019;49:347\u201380.","journal-title":"J Pharm Invest"},{"key":"1957_CR21","unstructured":"Wang Y, Qu W, Choi S. FDA\u2019s regulatory science program for generic PLA\/PLGA-based drug products. Am Pharm Rev 2016."},{"key":"1957_CR22","doi-asserted-by":"publisher","first-page":"e49635","DOI":"10.1371\/journal.pone.0049635","volume":"7","author":"GC Baltazar","year":"2012","unstructured":"Baltazar GC, Guha S, Lu W, Lim J, Boesze-Battaglia K, Laties AM, Tyagi P, Kompella UB, Mitchell CH. Acidic nanoparticles are trafficked to lysosomes and restore an acidic lysosomal pH and degradative function to compromised ARPE-19 cells. PLoS ONE. 2012;7:e49635.","journal-title":"PLoS ONE"},{"key":"1957_CR23","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.bioactmat.2022.05.030","volume":"17","author":"B Anand","year":"2022","unstructured":"Anand B, Wu Q, Nakhaei-Nejad M, Karthivashan G, Dorosh L, Amidian S, Dahal A, Li X, Stepanova M, Wille H. Significance of native PLGA nanoparticles in the treatment of Alzheimer\u2019s disease pathology. Bioactive Mater. 2022;17:506\u201325.","journal-title":"Bioactive Mater"},{"key":"1957_CR24","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/nan.12647","volume":"46","author":"Y Wang","year":"2020","unstructured":"Wang Y, Wu Q, Anand BG, Karthivashan G, Phukan G, Yang J, Thinakaran G, Westaway D, Kar S. Significance of cytosolic cathepsin D in Alzheimer\u2019s disease pathology: protective cellular effects of PLGA nanoparticles against \u03b2-amyloid\u2010toxicity. Neuropathol Appl Neurobiol. 2020;46:686\u2013706.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"1957_CR25","doi-asserted-by":"publisher","first-page":"10129","DOI":"10.1523\/JNEUROSCI.1202-06.2006","volume":"26","author":"H Oakley","year":"2006","unstructured":"Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L. Intraneuronal \u03b2-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer\u2019s disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26:10129\u201340.","journal-title":"J Neurosci"},{"key":"1957_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-022-01269-0","volume":"20","author":"PS Paul","year":"2022","unstructured":"Paul PS, Cho J-Y, Wu Q, Karthivashan G, Grabovac E, Wille H, Kulka M, Kar S. Unconjugated PLGA nanoparticles attenuate temperature-dependent \u03b2-amyloid aggregation and protect neurons against toxicity: implications for Alzheimer\u2019s disease pathology. J Nanobiotechnol. 2022;20:1\u201326.","journal-title":"J Nanobiotechnol"},{"key":"1957_CR27","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s11011-020-00608-0","volume":"35","author":"S Sarkar","year":"2020","unstructured":"Sarkar S, Raymick J, Cuevas E, Rosas-Hernandez H, Hanig J. Modification of methods to use Congo-red stain to simultaneously visualize amyloid plaques and tangles in human and rodent brain tissue sections. Metab Brain Dis. 2020;35:1371\u201383.","journal-title":"Metab Brain Dis"},{"key":"1957_CR28","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00401-020-02178-y","volume":"140","author":"N Younas","year":"2020","unstructured":"Younas N, Zafar S, Shafiq M, Noor A, Siegert A, Arora AS, Galkin A, Zafar A, Schmitz M, Stadelmann C. SFPQ and tau: critical factors contributing to rapid progression of Alzheimer\u2019s disease. Acta Neuropathol. 2020;140:317\u201339.","journal-title":"Acta Neuropathol"},{"key":"1957_CR29","doi-asserted-by":"crossref","unstructured":"Gallagher SR. Digital image processing and analysis with ImageJ. Current Protocols Essential Laboratory Techniques 2010, 3:A. 3\u00a0C. 1-A. 3\u00a0C. 24.","DOI":"10.1002\/9780470089941.eta03cs03"},{"key":"1957_CR30","doi-asserted-by":"crossref","unstructured":"Zeitvogel F, Obst M. ScatterJn: an ImageJ plugin for scatterplot-matrix analysis and classification of spatially resolved analytical microscopy data. Journal of Open Research Software 2016, 4.","DOI":"10.5334\/jors.89"},{"key":"1957_CR31","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.2147\/IJN.S164967","volume":"13","author":"S Clement","year":"2018","unstructured":"Clement S, Chen W, Deng W, Goldys EM. X-ray radiation-induced and targeted photodynamic therapy with folic acid-conjugated biodegradable nanoconstructs. Int J Nanomed. 2018;13:3553.","journal-title":"Int J Nanomed"},{"key":"1957_CR32","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","volume":"12","author":"V Villemagne","year":"2013","unstructured":"Villemagne V, Burnham S, Bourgeat P, Brown B, Ellis K, Salvado O, Szoeke C, Macaulay S, Martins R, Maruff P. Australian imaging biomarkers and lifestyle (AIBL) Research Group. Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: a prospective cohort study. Lancet Neurol. 2013;12:357\u201367.","journal-title":"Lancet Neurol"},{"key":"1957_CR33","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1212\/01.wnl.0000261919.22630.ea","volume":"68","author":"CC Rowe","year":"2007","unstructured":"Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, Cowie TF, Dickinson KL, Maruff P, Darby D. Imaging \u03b2-amyloid burden in aging and dementia. Neurology. 2007;68:1718\u201325.","journal-title":"Neurology"},{"key":"1957_CR34","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1093\/brain\/awn016","volume":"131","author":"MD Ikonomovic","year":"2008","unstructured":"Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolko S, Bi W, Paljug WR. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer\u2019s disease. Brain. 2008;131:1630\u201345.","journal-title":"Brain"},{"key":"1957_CR35","doi-asserted-by":"publisher","first-page":"7677","DOI":"10.1074\/jbc.M412056200","volume":"280","author":"A Lockhart","year":"2005","unstructured":"Lockhart A, Ye L, Judd DB, Merritt AT, Lowe PN, Morgenstern JL, Hong G, Gee AD, Brown J. Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer\u2019s disease PET imaging agents on \u03b2-amyloid peptide fibrils. J Biol Chem. 2005;280:7677\u201384.","journal-title":"J Biol Chem"},{"key":"1957_CR36","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.nucmedbio.2011.10.007","volume":"39","author":"MM Svedberg","year":"2012","unstructured":"Svedberg MM, Rahman O, Hall H. Preclinical studies of potential amyloid binding PET\/SPECT ligands in Alzheimer\u2019s disease. Nucl Med Biol. 2012;39:484\u2013501.","journal-title":"Nucl Med Biol"},{"key":"1957_CR37","doi-asserted-by":"publisher","first-page":"637386","DOI":"10.3389\/fdgth.2021.637386","volume":"3","author":"J Song","year":"2021","unstructured":"Song J, Zheng J, Li P, Lu X, Zhu G, Shen P. An effective multimodal image fusion method using MRI and PET for Alzheimer\u2019s disease diagnosis. Front Digit Health. 2021;3:637386.","journal-title":"Front Digit Health"},{"key":"1957_CR38","doi-asserted-by":"crossref","unstructured":"Li C, Song L, Zhu G, Hu B, Liu X, Wang Q. Alzheimer\u2019s level classification by 3D PMNet using PET\/MRI multi-modal images. In 2022 IEEE International Conference on Electrical Engineering, Big Data and Algorithms (EEBDA). IEEE; 2022: 1068\u20131073.","DOI":"10.1109\/EEBDA53927.2022.9744769"},{"key":"1957_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep24873","volume":"6","author":"G Plascencia-Villa","year":"2016","unstructured":"Plascencia-Villa G, Ponce A, Collingwood JF, Arellano-Jim\u00e9nez MJ, Zhu X, Rogers JT, Betancourt I, Jos\u00e9-Yacam\u00e1n M, Perry G. High-resolution analytical imaging and electron holography of magnetite particles in amyloid cores of Alzheimer\u2019s disease. Sci Rep. 2016;6:1\u201312.","journal-title":"Sci Rep"},{"key":"1957_CR40","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.tibtech.2017.06.002","volume":"35","author":"MJ Hajipour","year":"2017","unstructured":"Hajipour MJ, Santoso MR, Rezaee F, Aghaverdi H, Mahmoudi M, Perry G. Advances in Alzheimer\u2019s diagnosis and therapy: the implications of nanotechnology. Trends Biotechnol. 2017;35:937\u201353.","journal-title":"Trends Biotechnol"},{"key":"1957_CR41","doi-asserted-by":"crossref","unstructured":"Ning S, Jorfi M, Patel SR, Kim DY, Tanzi RE. Neurotechnological approaches to the diagnosis and treatment of Alzheimer\u2019s Disease. Front NeuroSci 2022, 16.","DOI":"10.3389\/fnins.2022.854992"},{"key":"1957_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-022-01524-4","volume":"20","author":"Y Ruan","year":"2022","unstructured":"Ruan Y, Xiong Y, Fang W, Yu Q, Mai Y, Cao Z, Wang K, Lei M, Xu J, Liu Y. Highly sensitive curcumin-conjugated nanotheranostic platform for detecting amyloid-beta plaques by magnetic resonance imaging and reversing cognitive deficits of Alzheimer\u2019s disease via NLRP3-inhibition. J Nanobiotechnol. 2022;20:1\u201321.","journal-title":"J Nanobiotechnol"},{"key":"1957_CR43","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1021\/acschemneuro.5b00214","volume":"7","author":"A Thapa","year":"2016","unstructured":"Thapa A, Jett SD, Chi EY. Curcumin attenuates amyloid-\u03b2 aggregate toxicity and modulates amyloid-\u03b2 aggregation pathway. ACS Chem Neurosci. 2016;7:56\u201368.","journal-title":"ACS Chem Neurosci"},{"key":"1957_CR44","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.3390\/ijms20092313","volume":"20","author":"S Andrade","year":"2019","unstructured":"Andrade S, Ramalho MJ, Loureiro JA, Pereira MdC. Natural compounds for Alzheimer\u2019s disease therapy: a systematic review of preclinical and clinical studies. Int J Mol Sci. 2019;20:2313.","journal-title":"Int J Mol Sci"},{"key":"1957_CR45","doi-asserted-by":"publisher","first-page":"111585","DOI":"10.1016\/j.ejmech.2019.111585","volume":"181","author":"Y Li","year":"2019","unstructured":"Li Y, Yan L, Cai J, Zhang W, Li L, Du Z, Dong C, Meunier B, Chen H. Development of novel theranostic agents for in vivo amyloid imaging and protective effects on human neuroblastoma cells. Eur J Med Chem. 2019;181:111585.","journal-title":"Eur J Med Chem"},{"key":"1957_CR46","doi-asserted-by":"publisher","first-page":"121830","DOI":"10.1016\/j.talanta.2020.121830","volume":"224","author":"X Wang","year":"2021","unstructured":"Wang X, Wang C, Chan H-N, Ashok I, Krishnamoorthi SK, Li M, Li H-W, Wong MS. Amyloid-\u03b2 oligomer targeted theranostic probes for in vivo NIR imaging and inhibition of self-aggregation and amyloid-\u03b2 induced ROS generation. Talanta. 2021;224:121830.","journal-title":"Talanta"},{"key":"1957_CR47","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1080\/10717544.2018.1461955","volume":"25","author":"S Fan","year":"2018","unstructured":"Fan S, Zheng Y, Liu X, Fang W, Chen X, Liao W, Jing X, Lei M, Tao E, Ma Q. Curcumin-loaded PLGA-PEG nanoparticles conjugated with B6 peptide for potential use in Alzheimer\u2019s disease. Drug Deliv. 2018;25:1091\u2013102.","journal-title":"Drug Deliv"},{"key":"1957_CR48","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.2147\/IJN.S171490","volume":"13","author":"M Silva-Abreu","year":"2018","unstructured":"Silva-Abreu M, Calpena AC, Andr\u00e9s-Benito P, Aso E, Romero IA, Roig-Carles D, Gromnicova R, Espina M, Ferrer I, Garc\u00eda ML. PPAR\u03b3 agonist-loaded PLGA-PEG nanocarriers as a potential treatment for Alzheimer\u2019s disease: in vitro and in vivo studies. Int J Nanomed. 2018;13:5577.","journal-title":"Int J Nanomed"},{"key":"1957_CR49","doi-asserted-by":"publisher","first-page":"e32616","DOI":"10.1371\/journal.pone.0032616","volume":"7","author":"A Mathew","year":"2012","unstructured":"Mathew A, Fukuda T, Nagaoka Y, Hasumura T, Morimoto H, Yoshida Y, Maekawa T, Venugopal K, Kumar DS. Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer\u2019s disease. PLoS ONE. 2012;7:e32616.","journal-title":"PLoS ONE"},{"key":"1957_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-018-0356-z","volume":"16","author":"E S\u00e1nchez-L\u00f3pez","year":"2018","unstructured":"S\u00e1nchez-L\u00f3pez E, Ettcheto M, Egea MA, Espina M, Cano A, Calpena AC, Camins A, Carmona N, Silva AM, Souto EB. Memantine loaded PLGA PEGylated nanoparticles for Alzheimer\u2019s disease: in vitro and in vivo characterization. J Nanobiotechnol. 2018;16:1\u201316.","journal-title":"J Nanobiotechnol"},{"key":"1957_CR51","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.nano.2019.02.004","volume":"17","author":"SG Jeon","year":"2019","unstructured":"Jeon SG, Cha M-Y, Kim J-i, Hwang TW, Kim KA, Kim TH, Song KC, Kim J-J, Moon M. Vitamin D-binding protein-loaded PLGA nanoparticles suppress Alzheimer\u2019s disease-related pathology in 5XFAD mice. Nanomed Nanotechnol Biol Med. 2019;17:297\u2013307.","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"1957_CR52","doi-asserted-by":"crossref","unstructured":"Xu R, Wang J, Xu J, Song X, Huang H, Feng Y, Fu C. Rhynchophylline loaded-mPEG-PLGA nanoparticles coated with tween-80 for preliminary study in Alzheimer\u2019s disease. International J nanomedicine 2020:1149\u201360.","DOI":"10.2147\/IJN.S236922"},{"key":"1957_CR53","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s11060-014-1658-0","volume":"121","author":"G Strohbehn","year":"2015","unstructured":"Strohbehn G, Coman D, Han L, Ragheb RR, Fahmy TM, Huttner AJ, Hyder F, Piepmeier JM, Saltzman WM, Zhou J. Imaging the delivery of brain-penetrating PLGA nanoparticles in the brain using magnetic resonance. J Neurooncol. 2015;121:441\u20139.","journal-title":"J Neurooncol"},{"key":"1957_CR54","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1021\/bc500315j","volume":"25","author":"RW Sirianni","year":"2014","unstructured":"Sirianni RW, Zheng M-Q, Patel TR, Shafbauer T, Zhou J, Saltzman WM, Carson RE, Huang Y. Radiolabeling of poly (lactic-co-glycolic acid)(PLGA) nanoparticles with biotinylated F-18 prosthetic groups and imaging of their delivery to the brain with positron emission tomography. Bioconj Chem. 2014;25:2157\u201365.","journal-title":"Bioconj Chem"},{"key":"1957_CR55","doi-asserted-by":"publisher","first-page":"12076","DOI":"10.1039\/C5NR03474D","volume":"7","author":"C Fornaguera","year":"2015","unstructured":"Fornaguera C, Feiner-Gracia N, Calder\u00f3 G, Garc\u00eda-Celma M, Solans C. Galantamine-loaded PLGA nanoparticles, from nano-emulsion templating, as novel advanced drug delivery systems to treat neurodegenerative diseases. Nanoscale. 2015;7:12076\u201384.","journal-title":"Nanoscale"},{"key":"1957_CR56","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.colsurfb.2016.08.052","volume":"148","author":"D Sun","year":"2016","unstructured":"Sun D, Li N, Zhang W, Zhao Z, Mou Z, Huang D, Liu J, Wang W. Design of PLGA-functionalized quercetin nanoparticles for potential use in Alzheimer\u2019s disease. Colloids Surf B Biointerfaces. 2016;148:116\u201329.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"1957_CR57","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00702-016-1527-4","volume":"124","author":"I Baysal","year":"2017","unstructured":"Baysal I, Ucar G, Gultekinoglu M, Ulubayram K, Yabanoglu-Ciftci S. Donepezil loaded PLGA-b-PEG nanoparticles: their ability to induce destabilization of amyloid fibrils and to cross blood brain barrier in vitro. J Neural Transm. 2017;124:33\u201345.","journal-title":"J Neural Transm"},{"key":"1957_CR58","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1080\/15548627.2015.1136769","volume":"12","author":"M Bourdenx","year":"2016","unstructured":"Bourdenx M, Daniel J, Genin E, Soria FN, Blanchard-Desce M, Bezard E, Dehay B. Nanoparticles restore lysosomal acidification defects: implications for Parkinson and other lysosomal-related diseases. Autophagy. 2016;12:472\u201383.","journal-title":"Autophagy"}],"updated-by":[{"DOI":"10.1186\/s12951-023-02009-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T00:00:00Z","timestamp":1691020800000}}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-023-01957-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-023-01957-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-023-01957-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T15:24:15Z","timestamp":1700407455000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-023-01957-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,10]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1957"],"URL":"https:\/\/doi.org\/10.1186\/s12951-023-01957-5","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12951-023-02009-8","asserted-by":"object"}]},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,10]]},"assertion":[{"value":"20 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12951-023-02009-8","URL":"https:\/\/doi.org\/10.1186\/s12951-023-02009-8","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare no competing financial interests or personal relationships that could influence the work reported in this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of competing interest"}}],"article-number":"216"}}